If approved, Zydus Cadila’s willing to manufacture 120 million doses annually and would make Zycov-D the fifth vaccine to be administered in India after Covaxin, Covishield, Sputnik V, and Moderna.
Gujarat-based drugmaker Zydus Cadila has applied to the DCGI for an emergency nod for its vaccine, Zycov-D, its DNA vaccine against COVID-19 for those aged 12 years and above, news agencies reported on Thursday.
Zydus Cadila applies for Emergency Use Authorisation (EUA) seeking approval from the Drugs Controller General of India (DCGI) for the launch of their DNA vaccine for 12 years & above. The vaccine has completed the third phase of trial.#COVID19 pic.twitter.com/LDlsSkG3zF
— ANI (@ANI) July 1, 2021
The company presented interim results from Phase-III clinical trials in over 28,000 volunteers, Reuters said, adding that the study demonstrates safety and efficacy in the interim data.
If approved, Zydus Cadila’s willing to manufacture 120 million doses annually and would make Zycov-D the fifth vaccine to be administered in India after Covaxin, Covishield, Sputnik V, and Moderna.
Also Read: “Rise In Input Costs”: Amul Hikes Milk Prices Across India
The study was carried out “during the peak of the second wave of COVID-19 (in India), reaffirming the vaccine’s efficacy against the new mutant strains especially the Delta variant,” Zydus Cadila said in a statement to the stock exchanges.
Coronavirus cases in India dropped from a devastating peak in April and May, however, experts have warned of a third wave and reiterated that widespread vaccination remains one of the best defences against the pandemic.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
